ArticleNeuro-oncology2019
Using germline variants to estimate glioma and subtype risks.
Article in Neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma.Neuro-oncology · 2026Article
- Histogram analysis of IVIM MRI for differentiating glioma IDH-1 status, grade, and Ki-67 expression: a comparison of bi-exponential models at multiple B-value.BMC medical imaging · 2025Article
- Integration of MRI radiomics and germline genetics to predict the IDH mutation status of gliomas.NPJ precision oncology · 2025Article
- Genome-wide polygenic risk scores predict risk of glioma and molecular subtypes.Neuro-oncology · 2024Article
- Co-expression in tissue-specific gene networks links genes in cancer-susceptibility loci to known somatic driver genes.BMC medical genomics · 2024Article
- Genome-wide Polygenic Risk Scores Predict Risk of Glioma and Molecular Subtypes.medRxiv : the preprint server for health sciences · 2024Article
- Diagnostic challenges in complicated case of glioblastoma.Pathology oncology research : POR · 2024Article
- The Importance of Quality Assurance in Radiation Oncology Clinical Trials.Seminars in radiation oncology · 2023Review
- Deciphering gliomagenesis from genome-wide association studies.Neuro-oncology · 2023Article
- Epidemiological characteristics and genetic alterations in adult diffuse glioma in East Asian populations.Cancer biology & medicine · 2022Review
- Prediagnostic biomarkers for early detection of glioma-using case-control studies from cohorts as study approach.Neuro-oncology advances · 2022Article
- Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker.Clinical epigenetics · 2022Article
- Is intracranial volume a risk factor for IDH-mutant low-grade glioma? A case-control study.Journal of neuro-oncology · 2022Article
- Inherited genetics of adult diffuse glioma and polygenic risk scores-a review.Neuro-oncology practice · 2022Review
- Radiation Oncology: Future Vision for Quality Assurance and Data Management in Clinical Trials and Translational Science.Frontiers in oncology · 2022Review
- Random effect based tests for multinomial logistic regression in genetic association studies.Genetic epidemiology · 2021Article
- Article
- Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.Neuro-oncology · 2021Article
- Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era.FEBS letters · 2020Review
- Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C.Neuro-oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundTwenty-five single nucleotide polymorphisms (SNPs) are associated with adult diffuse glioma risk. We hypothesized that the inclusion of these 25 SNPs with age at diagnosis and sex could estimate risk of glioma as well as identify glioma subtypes.
methodsCase-control design and multinomial logistic regression were used to develop models to estimate the risk of glioma development while accounting for histologic and molecular subtypes. Case-case design and logistic regression were used to develop models to predict isocitrate dehydrogenase (IDH) mutation status. A total of 1273 glioma cases and 443 controls from Mayo Clinic were used in the discovery set, and 852 glioma cases and 231 controls from UCSF were used in the validation set. All samples were genotyped using a custom Illumina OncoArray.
resultsPatients in the highest 5% of the risk score had more than a 14-fold increase in relative risk of developing an IDH mutant glioma. Large differences in lifetime absolute risk were observed at the extremes of the risk score percentile. For both IDH mutant 1p/19q non-codeleted glioma and IDH mutant 1p/19q codeleted glioma, the lifetime risk increased from almost null to 2.3% and almost null to 1.7%, respectively. The SNP-based model that predicted IDH mutation status had a validation concordance index of 0.85.
conclusionsThese results suggest that germline genotyping can provide new tools for the initial management of newly discovered brain lesions. Given the low lifetime risk of glioma, risk scores will not be useful for population screening; however, they may be useful in certain clinically defined high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.